The total number of NACDS RxIMPACT 2019 in-district events to promote DIR relief priorities now stands at 72—and counting.
Members of Congress were able to grasp firsthand critical pharmacy public policy issues when they toured pharmacies in their home states and congressional districts.
During the Fourth of July congressional recess, members of Congress learned firsthand about key pharmacy issues—particularly about the need for direct and indirect remuneration (DIR) fee relief as part of a drug-pricing legislative package.
DIR Fee Relief is Focus of Largest-Ever NACDS RxIMPACT Push Effort underway to help advance Phair Pricing Act
DIR fee relief is motivating a record-breaking NACDS RxIMPACT Congressional letter-writing campaign. The effort to end the abuse of DIR fees includes three focuses right now. Learn more.
NACDS emphasized the need for Congress to address direct and indirect remuneration (DIR) fee relief as it considers solutions to reduce healthcare costs.
NACDS recommended several measures to lower prescription drug prices and improve patient health--including DIR fee relief--to the House Committee on Energy and Commerce Subcommittee on Health.
Houston’s Retail, Health and Wellness Scene Under NACDS Microscope NACDS Retail Advisory Board brings Market Immersion series to compelling location
The NACDS Retail Advisory Board brings its Market Immersion series to a highly compelling location, May 13-15, 2019.